



Supplementary Figure 6. CSR defects in *ROD1^{exon3-/-}* mice. **(a)** The Ig concentration was quantified by ELISA with blood from WT and *ROD1^{exon3-/-}* mice. Blood samples were harvested from 8-week-old mice (n = 6 for each genotype). * $P < 0.05$, ** $P < 0.01$ and $P > 0.05$ was non-significant (n.s) as determined by two-tailed Student's *t*-test. **(b)** CFSE staining of splenic B cells before (day 0) and after LPS stimulation (day 3). B cells were isolated from age-matched 8-week-old WT and *ROD1^{exon3-/-}* mice. Scale bar: 50 μ m. **(c)** Flow cytometric analysis of splenic B cells stained with CFSE before (red) and after (blue) LPS treatment. A portion of the B cells was harvested and measured at day 0. The rest of the population was stimulated with LPS and allowed to proliferate for 3 days. **(d)** The quantification of B cell proliferation for WT and *ROD1^{exon3-/-}* mice. The y-axis represents the intensity of CFSE dye (n = 4). **(e)** RT-qPCR examination of germline transcripts containing I μ and C_H exons of the same isotype in *ex vivo* cultured splenic B

cells. **(f)** Flow cytometric analysis of IgE and IgG2b with *ex vivo* cultured splenic B cells activated either by LPS or LPS plus IL4. **(g)** Quantification of IgE and IgG2b CSR efficiency as shown in (f). * $P < 0.05$ by two-tailed Student's *t*-test. (f) and (g) are related to Fig. 2c.